Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News ProMIS Neurosciences Inc PMN

Healthcare Biotechnology
ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine... see more

Recent & Breaking News (NDAQ:PMN)

ProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALS

GlobeNewswire 10 days ago

ProMIS Neurosciences to Present in Upcoming Investor Conferences in April 

GlobeNewswire April 4, 2024

ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights

GlobeNewswire April 1, 2024

ProMIS Neurosciences Strengthens Global Intellectual Property Portfolio

GlobeNewswire March 11, 2024

ProMIS Neurosciences to Present at the 2024 BIO CEO & Investor Conference

GlobeNewswire February 22, 2024

ProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein Vaccine

GlobeNewswire January 22, 2024

ProMIS Neurosciences Issues Letter to Shareholders

GlobeNewswire January 8, 2024

ProMIS Neurosciences, Inc. Announces Leadership Transition

GlobeNewswire January 3, 2024

ProMIS Neurosciences Announces Publication on Novel Target for ALS

GlobeNewswire December 20, 2023

ProMIS Neurosciences Doses First Subjects in Phase 1a Clinical Trial of PMN310 to Treat Alzheimer's Disease

GlobeNewswire November 20, 2023

ProMIS Neurosciences Announces Third Quarter 2023 Financial Results and Recent Highlights

GlobeNewswire November 14, 2023

ProMIS Neurosciences Closes $20.4 Million Private Placement Financing

GlobeNewswire September 8, 2023

ProMIS Neurosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference

GlobeNewswire September 6, 2023

ProMIS Neurosciences Announces $20.4 Million Private Placement Financing

GlobeNewswire August 21, 2023

ProMIS Neurosciences Announces Second Quarter 2023 Financial Results and Recent Highlights

GlobeNewswire August 14, 2023

New Alzheimer’s drug data shows better treatment is closer than ever

Jonathon Brown July 18, 2023

ProMIS Showcases Preclinical Data at the Alzheimer's Association International Conference 2023 on Computationally-Derived Antibody and Vaccine from Alzheimer's Pipeline

GlobeNewswire July 17, 2023

ProMIS Announces Completion of Continuance

GlobeNewswire July 14, 2023

ProMIS Neurosciences to Consolidate Trading on the Nasdaq Exchange

GlobeNewswire July 10, 2023

ProMIS Neurosciences Holds Annual Meeting of Shareholders All Resolutions Approved

GlobeNewswire June 30, 2023